Point Therapeutics Inc. has initiated a phase 2 clinical trial of the company's lead therapeutic compound, talabostat (PT-100), for treatment of advanced metastatic melanoma.
Editorial Advisory Board Insights for Eczema Awareness Month: Raj Chovatiya, MD, PhD
The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis
Derm In The News: September 24-30
The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques
The Importance of Timing With Live Vaccinations in Pediatric Atopic Dermatitis
Evaluating Efficacy of Trifarotene in Latin American Patients With Acne
2 Clarke Drive Cranbury, NJ 08512